Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
Altimmune, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $3.01
-6.2% in 3d after detection
Post-detection moves
1h
—
1d
-2.4%
3d
-6.2%
7d
+0.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS